Skip to main content

Table 2 Adverse events

From: Retrospective case note review of chronic spontaneous urticaria outcomes and adverse effects in patients treated with omalizumab or ciclosporin in UK secondary care

AE symptom (not mutually exclusive)

No. symptoms reported

No. patients

Omalizumab

 

N = 17a

 Skin (rash, erythema, wheals, eczema, urticaria/itching)

8

4

 Angioedema

6

3

 Anaphylaxis

3

2

 Headaches

2

2

 Hot/flushed

2

2

 Omalizumab reaction (not specified)

1

1

 Palpitations

2

2

 Pregnancy

2

2

 ”Fuzzy head”

1

1

 Biliary colic

1

1

 Conjunctival haemorrhage

1

1

 Erectile dysfunction

1

1

 Hair loss

1

1

 Injection site reaction

1

1

 Sinus bradycardia

1

1

 Shortness of breath

1

1

 Tachycardia

1

1

 Type III Immune complex medicine reaction

1

1

 Total—omalizumab

36

Ciclosporin

 

N = 28a

 Hypertension

8

8

 Fatigue/tiredness

6

6

 GI

4

4

 Headaches

4

4

 Altered sensation

3

2

 Pregnancy

2

2

 Worsening renal function

2

2

 Dizziness/collapse

2

2

 Excess hair growth

1

1

 Increased ESR

1

1

 Lower back pain

1

1

 Loin pain

1

1

 Lumpectomy

1

1

 Memory problems

1

1

 Miscarriage

1

1

 Muscle weakness

1

1

 Side effects

1

1

 UTI

1

1

 Peripheral oedema

1

1

 Poor wound healing

1

1

 Mild stroke

1

1

 Urticarial flare

1

1

 Gum soreness and swelling

1

1

 Unwell

1

1

 Visual disturbance

1

1

 Seborrheic keratosis

1

1

 Total—ciclosporin

49

  1. aThe number of patients reporting an AE is not the total in this column because some patients experienced more than one adverse event symptom.